Objectives. Exposure and response prevention (ERP) remains the most empirically supported psychological treatment for obsessive compulsive disorder (OCD). Clinical guidelines recommend the addition of cognitive approaches to ERP although the presumed additive benefits have not been directly tested. The aim of this was to compare a treatment that integrated cognitive therapy with ERP (ERP + CT) to traditional, manualized ERP to test the additive benefits.
Exposure and response prevention (ERP) treatment is the most empirically supported psychotherapeutic intervention for obsessive compulsive disorder (OCD) and is considered a frontline treatment in international clinical guidelines (American Psychiatric Association, 2007; Katzman et al., 2014; NICE, 2005) . Studies demonstrate that ERP leads to clinically significant and lasting change in OCD symptoms irrespective of symptom presentation and severity, timing of delivery (intensive vs. outpatient), and comorbidity status (Eddy, Dutra, Bradley, & Westen, 2004; Olatunji, Davis, Powers, & Smits, 2013) . Cognitive therapy (CT) is less frequently examined and is less empirically established as a treatment for OCD, although it has also been found to be an effective treatment for OCD (e.g., Anholt et al., 2007; Cottraux et al., 2001; Whittal, Thordarson, & McLean, 2005; Whittal, Woody, McLean, Rachman, & Robichaud, 2010) . While the aim of ERP is to reduce anxiety through prolonged exposure to anxiety-inducing stimuli while preventing overt or covert rituals, the aim of CT for OCD is to reduce obsessions and compulsions by targeting the maladaptive appraisals and dysfunctional beliefs that are implicated in the development and maintenance of obsessive-compulsive (O-C) symptoms. In the past two decades, cognitive features have been demonstrated to be associated with the maintenance of obsessions and compulsions (Obsessive Compulsive Cognitions Working Group, 1997 Rachman, 1997; Salkovskis, 1985) and have been directly targeted in theoretically based manualized CT approaches for OCD (Clark, 2004; Steketee, Frost, Rh eaume, & Wilhelm, 1998) .
The majority of controlled trials and meta-analytic summaries have examined ERP versus cognitive therapy as two distinct treatments for OCD. When compared, no differences have been found, with both treatments demonstrating significant and equivalent efficacy (Eddy et al., 2004; Olatunji et al., 2013; Rosa-Alc azar, S anchez-Meca, G omez-Conesa, & Mar ın-Mart ınez, 2008) . However, an alternative approach that has been proposed in prominent treatment guidelines (NICE, 2005) is to integrate CT and ERP into a comprehensive integrated cognitive behavioural therapy (CBT) approach. With varying degrees of CT/ERP integration (Cordioli et al., 2003; O'Connor et al., 2006) , clinical effectiveness of the approach has been demonstrated (Anderson & Rees, 2007; Braga et al., 2016; Cordioli et al., 2003; Freeston et al., 1997; Gomes et al., 2016; Jaurrieta et al., 2008; O'Connor, Todorov, Robillard, Borgeat, & Brault, 1999; O'Connor et al., 2006) . As well, a recent mega-analysis combining information from both controlled trials and clinical settings found that integrated CBT, CT, and ERP all had large effect sizes (Steketee, Siev, Yovel, Lit, & Wilhelm, 2018) . As of yet, no randomized control study has directly tested whether integrated, manualized CBT produces enhanced effectiveness beyond ERP alone.
The aim of this study was to examine whether the addition of manualized cognitive therapy assessment, conceptualization, and intervention strategies to manual-based ERP results in additional treatment benefits beyond ERP alone to the extent that would justify adding new elements to an already effective therapy. It was hypothesized that the integrated ERP + CT condition would result in better treatment outcomes than ERP alone in terms of symptom improvement and reduction in cognitive markers of OCD vulnerability. A second purpose of the study was to test distinction versus uniformity in treatment effects across different obsessive-compulsive presentations. Past research has demonstrated (Abramowitz, Franklin, Schwartz, & Furr, 2003) differential treatment effects in ERP based on O-C symptom presentation although no published research has examined whether adding CT to ERP produces uniform or more symptom dimensionspecific treatment outcomes.
Methods
Participants and study design Recruitment Participants were recruited from a large community-based OCD and Anxiety Disorders Clinic with appropriate institutional review board approval. Once informed consent was obtained, participants were administered the Structured Clinical Interview for Axis 1 Disorders (SCID-1/P version 2.0) and a YBOCS clinician-rated interview. Participants were considered for this study according to the following criteria. Inclusion criteria were as follows: (1) meeting DSM-IV-TR (American Psychiatric Association, 2000) criteria for OCD based on the SCID, (2) between the ages of 18 and 65, (3) experiencing clinically significant obsessive-compulsive symptoms as defined by a Y-BOCS score >16, (4) able to provide informed consent, and (5) on stable medications, as defined by no change in medication type or dose during 8 weeks before treatment. Exclusion criteria were as follows: (1) past or present treatment with behaviour therapy or cognitive behaviour therapy, (2) concurrent diagnosis of a mood disorder, schizophrenia or other psychotic disorders, (3) active substance abuse/dependence within 6-months of study entry, (4) suspected organic pathology, (5) primary hoarding obsessions/compulsions. All inclusion and exclusion criteria were outlined in the advertisements of the study.
Procedure
Ethical approval for this study was provided by a university-affiliated Research Ethics Board (Ref: . Stratified random sampling was used to assign eligible participants to one of two conditions: ERP or ERP + CT. Randomization was conducted by computer-generated blocks of random numbers. An independent assessor not involved in treatment or in post-treatment assessments performed the randomization. Assessment teams at each phase of the study did not overlap and all attempts to ensure participant condition masking was undertaken. Two hundred and twelve participants were assessed for eligibility for this study. Of these, 35 were excluded at the phone screen phase, 30 were excluded after the SCID-interview phase, and 20 were excluded after the clinicianadministered Y-BOCS. The remaining 127 participants were accepted into the study and were randomized into the two treatment conditions: ERP (n = 62) and ERP + CT (n = 65). Of the participants who completed the assessment phase and were successfully randomized the dropout rate was not significantly different by treatment condition, (X 2 = 3.17, p > .05) and the overall number of treatment sessions received in the ERP (M = 14.6, SD = 2.2) and ERP + CT (M = 15.3, SD = 1.5) conditions were equivalent, F (1, 94) = 2.87, p > .05. A detailed overview of recruitment and retention for the study is illustrated in Figure 1 . The study resulted in a final intent-to-treat (ITT) sample of 124 and a final completer sample of 94 participants, 42 who were in the ERP group and 52 who were in the ERP + CT group. Demographic features for the completers sample are presented in Table 1 . Additionally, 31.5% of the sample had a secondary SCID diagnosis at the time of the study with the most commonly occurring comorbidities being: social anxiety disorder (8.9%); specific phobia (5.6%); and generalized anxiety disorder (2.4%).
Medication use
Participants taking psychotropic medications were advised not to make any changes during the active phase of their treatment although all changes to medications were monitored and recorded by team therapists and verified by research staff across the study duration. A series of ANOVAs and Chi squares were computed to test for group differences on the type of medication, current medication usage, dosage levels at the time of randomization, changes in medication while in treatment, and number of past SSRIs, other antidepressants and anxiolytics and antipsychotics. Twenty-seven (64.29%) participants in the ERP condition and 36 (69.23%) in the ERP + CT treatment condition were on medications. No differences were observed between the two groups on any of the medication variables (p's > .05). A summary of these analyses is shown in Table 2 .
Treatment conditions
Exposure and response prevention Exposure and response prevention was conducted according to the manual developed, widely tested and disseminated by Kozak and Foa (1997) and consistent with Foa, Yadin, and Lichner (2012) . The intervention consisted of 16 60-min weekly sessions in individual outpatient format. ERP entailed prolonged exposure to obsessional cues that induced discomfort and strict abstinence of ritualizing behaviour until the discomfort abated (leading to habituation of fears). Exposure proceeded in a hierarchical fashion. Although informal challenging of cognitions can be a component of ERP, such as by guiding participants towards noticing whether their hypotheses related to the exposure were supported, formal and structured cognitive restructuring techniques as described below were not a component of the ERP group. Participants were also instructed to practice exposure exercises between sessions, upwards of 1-2 hrs per day for a minimum of four times per week. The final phase of treatment focused on relapse prevention.
Integrated treatment: exposure and response prevention plus cognitive therapy The integrated ERP + CT was conducted according to the same treatment manual based on Kozak and Foa (1997) described above. It was based on providing psychoeducation, monitoring obsessional triggers, developing hierarchies, teaching anxiety (SUDS) ratings, and monitoring SUDS ratings during exposure tasks in-session and as homework. Exposure tasks included exposure to obsessional cues and ritual prevention. However, the theoretical framework for all exposure tasks in-session and as part of homework was not on habituation but rather using the exposure task to activate cognitive appraisals and obsessional beliefs for further questioning, evidence-gathering and reframing including appraisals pertaining to the ability to cope with anxious arousal when refraining from rituals. The delivery of in-session and between-session exposures in the early phase of treatment was then followed by an increasing integration of cognitive principles and approaches from sessions 4 to 14 based on approaches outlined by Clark (2004) , Rachman (1998 Rachman ( , 2003 , Salkovskis (1999) and Steketee et al. (1998) targeting appraisals and dysfunctional beliefs related to the six domains outlined by the OCCWG (1997, 2001 ). Specific cognitive strategies were included to normalize intrusions, target obsessional appraisals of intrusions, identify and change cognitive distortions, and test alternative appraisals/interpretations of intrusions during in-session and betweensession exposures. Further, obsessive beliefs pertaining to inflated responsibility, overestimation of threat, perfectionism, need for certainty, and overimportance and need to control thoughts were targeted as previously outlined (Clark, 2004; Rachman, 1998 Rachman, , 2003 Salkovskis, 1999; Steketee et al., 1998) . The final stage of treatment (Sessions 15 and 16) focused on relapse prevention including ERP and CT features. Like the ERP condition, this intervention consisted of 16 60-min sessions in individual format on a weekly basis.
Therapists
To control for allegiance and cross-contamination of protocols within the same site, two senior M.D./Ph.D. therapists with allegiance to ERP directed the ERP condition and two senior M.D./Ph.D. level therapists with expertise in CT and integrated ERP + CT for OCD directed the integrated ERP + CT condition. Other therapists (n = 4) were matched for their level of expertise and familiarity with ERP and ERP + CT in the two conditions. Amongst the eight trained community psychiatrists and psychologists responsible for delivering treatment, the mean age was 38 years (SD = 7.39 years) with 7.68 years (SD = 4.69 years) of specialized ERP/ERP + CT experience.
Treatment adherence and integrity
To examine adherence to the treatment protocols, items for the adherence rating scale were generated from the treatment manuals. Raters who were separate from the study team and blind to participant condition, therapist protocol, and the study hypotheses evaluated 200 randomly selected audiotapes of ERP (n = 100) and ERP + CT (n = 100) treatment sessions stratified by phase of treatment (early, middle, late). A reliability check on tape ratings was achieved by having a second rater trained in the ERP and ERP + CT protocols rate 20 of the 200 tapes (10 per condition) and the inter-rater reliability was determined to be acceptable (r = .97). Overall, adherence ratings across the 16-session protocol was determined to be excellent and equivalent between the ERP (M = 87.89, SE = 1.467) and ERP + CT conditions (M = 87.61, SE = 1.47), F(1, 198) = 0.02, p > .05. A final evaluation of treatment fidelity was the determination of whether the ERP condition included formal cognitive restructuring techniques at the appraisal or belief level. Because the ERP manual of Kozak and Foa (1997) allows for cognitive challenging of estimates of threat during in-session and between-session exposure tasks, independent raters were requested to identify all sessions that included more formal cognitive therapy with structured interventions for negative appraisals of intrusions and obsessive beliefs. None of the ERP tapes (n = 100) were identified as having formal cognitive therapy elements. Finally, there were no differences in outcomes between therapists in ERP or ERP + CT (p > .05).
Measures
Structured Clinical Interview for DSM-IV Disorders (SCID-I/Pl; First, Spitzer, Gibbon, & Williams, 1996 , 2002 The SCID-I interviews were administered by research staff whom had received extensive formal training in the administration and scoring of the interview protocol with OCD and anxiety disordered patient populations, and who had completed a rigorous inter-rater reliability training programme prior to administration. Additionally, the SCID-I assessors attended weekly clinical case conference meetings with senior psychologists who specialized in the assessment and treatment of anxiety disorders, to establish consensus principal and secondary psychiatric diagnoses.
Yale-Brown Obsessive Compulsive Scale (Y-BOCS; Goodman, Price, Rasmussen, Mazure, Delgado, et al., 1989; Goodman, Price, Rasmussen, Mazure, Fleischmann, et al., 1989) The Y-BOCS is standardized rating scale designed to identify frequency, interference, and distress associated with obsessions and compulsions. The Y-BOCS consists of 10 items pertaining to obsessions and compulsions that are rated on a 5-point Likert scale ranging from 0 (no symptoms) to 4 (severe symptoms). The Y-BOCS symptom checklist was also used for subtyping analysis. The Y-BOCS has been shown to possess high internal consistency and validity (Goodman, Price, Rasmussen, Mazure, Delgado, et al., 1989; Goodman, Price, Rasmussen, Mazure, Fleischmann, et al., 1989) . Prior to the initiation of the study, an extensive training programme was conducted in the administration and coding of audiotaped Y-BOCS interviews. Inter-rater reliability based on tape ratings of the Y-BOCS total was excellent (r = .98).
The pre-treatment Y-BOCS was administered prior to randomization and so blinding was not necessary for this phase. However, assessors administering the post-treatment Y-BOCS were blind to participant condition and were unaware of the study hypotheses. In an effort to maintain the blind, the participants were requested not to reveal the name of their therapist or the nature of their clinical care during the Y-BOCS interview. Blind assessors were not members of the study team and had no contact with team therapists or study participants.
The Obsessional Belief Questionnaire (OBQ-87; OCCWG, 1997 OCCWG, , 2001 OCCWG, , 2003 The Obsessional Belief Questionnaire (OBQ) is an 87-item self-report questionnaire designed to assess the extent to which respondents agree or disagree with various attitudes and beliefs related to obsessional thoughts. The OBQ-87 comprises three factors: Responsibility/Threat Estimation (e.g., 'Harmful events will happen unless I'm careful'), Perfectionism/Certainty (e.g., 'Things are not right if they are not perfect'), and Importance/Control of Thoughts (e.g., 'A bad thought is morally no different than a bad deed'). Respondents indicate their level of agreement with items on a 7-point rating scale. Higher scores indicate a greater strength of beliefs. The OBQ is internally consistent and evidences good test-retest reliability, convergent validity, and discriminant validity (OCCWG, 2005) . In this study, internal consistency (Cronbach a) for the total OBQ of .97 was deemed acceptable.
Beck Depression Inventory-II (Beck & Steer, 1987) The Beck Depression Inventory-II (BDI-II) is a 21-item self-report instrument designed to assess the severity of depressive symptoms over the preceding week. The BDI-II has been shown to be a reliable and well-validated measure of depressive symptomatology (Beck, Steer, & Carbin, 1988 ).
Beck Anxiety Inventory (Beck & Steer, 1990 ) The Beck Anxiety Inventory (BAI) consists of 21 self-reported items employed to assess the intensity of physical and cognitive anxiety symptoms during the past week. A variety of studies have supported the reliability and validity of the BAI as a measure of anxiety in both clinical and non-clinical samples (Beck, Epstein, Brown, & Steer, 1988; Borden, Peterson, & Jackson, 1991) .
Psychotherapy Expectancies Inventory -Revised (Rickers-Ovsiankina, Geller, Berzins, & Rogers, 1971) The Psychotherapy Expectancies Inventory -Revised (PEI-R) is a 30-item self-report questionnaire consisting of 24 keyed items and six filler items. It measures client expectations about the likelihood that certain interactions will take place during therapy.
Statistical analyses
A power analysis revealed that in order to detect a potential medium-to-large effect size difference between ERP and ERP + CT at post-treatment on the principal outcome measure with power of .80 and Alpha set at .05, 32 participants per condition were required. The final ITT sample (n = 127) and the final sample of treatment completers (n = 94) provided excellent power to test differences in the sample as a whole, as well as in distinct symptom groups (e.g., contamination/washing vs. doubting/checking etc.). In the ITT analyses, participants who withdrew prior to completing the treatment were retained by carrying forward the last obtained score. For the analyses on treatment completers, no data were missing for the clinician-rated Y-BOCS, which was their principal outcome measure. However, where data were missing on self-report measures, the last observation was carried forward. To test for between-group treatment differences at outcome, repeated-measures multivariate analyses of variance (MANOVAs) were conducted with treatment modality as the between-group variable and symptom (Y-BOCS) and cognitive (OBQ) change scores as the repeated within-group variables. Chisquare tests were conducted to determine whether the number of participants being deemed 'treatment responders' differed by condition. As a confirmation of blinding, assessors did not guess participant treatment condition beyond chance and there were no significant differences in correct guesses between treatment conditions (p's > .05)
Results

Treatment credibility
Treatment credibility was measured using the PEI-R (Rickers-Ovsiankina et al., 1971 ). There were no differences between the ERP (M = 104.2, SD = 23.7) and ERP + CT (M = 105.4, SD = 20.5) conditions for the ITT sample, F(1, 124) = 0.10, p > .05, or between ERP (M = 103.6, SD = 22.4) and ERP + CT (M = 104.5, SD = 21.2) conditions for treatment completers, F(1, 94) = 0.04, p > .05 on pre-treatment ratings of expectations to benefit from treatment.
Treatment outcomes: Y-BOCS change and responder status
The study measures pre-and post-treatment means, standard deviations, and effect sizes for study completers according to treatment condition are presented in Table 3 . There were no significant differences between treatment conditions on any of the study measures (all p's > .05) within the ITT or completers samples at baseline. Outcomes by OCD symptom subtype group Scores on the Y-BOCS symptom checklist were quantified in a similar manner to Baer (1994) and Calamari, Wiegartz, and Janeck (1999) into 15 derived categories. Responses on the 15 symptom categories of the Y-BOCS were scored '0' (not endorsed), '1' (the patient endorsed at least one symptom, but the category was not considered primary) and '2' (symptoms were endorsed and the category was identified as the principal problem in treatment). A symptom category was considered principal if was rated as '2' and was the principal focus in treatment. This procedure resulted in the following subtype classification: contamination/washing (n = 40), doubting-harming/checking (n = 45), symmetry/ordering (n = 20), pure obsessions/'bad thoughts' (n = 13), and miscellaneous (n = 6). No patients had primary hoarding symptoms. Analyses were conducted on the four principal symptom dimensions excluding the miscellaneous group. MANOVAs were repeated with Y-BOCS scores at pre-treatment and post-treatment as the within-subject repeated measures and treatment condition and symptom subtype group as the between-group variables. In the ITT, Wilks' k = .93, F(4, 114) = 8.43, p < .005 and treatment completer samples, Wilks' k = .93, F(4, 84) = 9.43, p < .005 the original Y-BOCS change by treatment condition multivariate interactions were retained, although there were no Y-BOCS change by symptom subtype multivariate effects (p's > .05) or Y-BOCS by symptom subtype by treatment condition multivariate effects (p's > .05).
Intent-to-treat
Treatment responder status by condition
Treatment responder status was determined using per cent reductions as a measure of outcome. Per cent reductions used were based on a signal detection study using 'gold standard' criteria from the Clinical Global Impressions scale, which found that 30% reduction is optimal for determining clinical improvement and 50% reduction provides indication of 'mild illness' at post-treatment (Tolin, Abramowitz, & Diefenbach, 2005) .
Percentage reductions
For treatment completers, the rates of significant response were 65.4% for the ERP + CT group and 45.5% for the ERP group, and based on logistic regression this rate was not significant, OR = 2.27, p = 0.052. In terms of those reaching mild illness status, more occurred in the ERP + CT group (44.2%) compared to ERP (22.7%), OR = 2.70, p = .03.
Effects on obsessive beliefs
Intent-to-treat A repeated-measures MANOVA on the OBQ scores for the ITT sample indicated that both treatments produced large and significant effects on OBQ scores, Wilks' k = .69, F(1, 121) = 53.98, p < .001 although the ERP + CT produced greater change on obsessive beliefs compared to ERP as demonstrated in a OBQ change by treatment condition multivariate interaction, Wilks' k = .95, F(1, 117) = 6.28, p < .01.
Treatment completers
The same MANOVA with treatment completers similarly revealed a main effect for OBQ change, Wilks' k = .62, F(1, 92) = 57.01, p < .001 and a two-way OBQ change by treatment condition interaction, Wilks' k = .95, F(1, 92) = 4.86, p < .05 with the ERP + CT group producing greater change on obsessive beliefs than the ERP group.
Effects on anxiety and depression Intent-to-treat A repeated-measures MANOVA demonstrated that both treatment conditions produced significant change on anxiety, Wilks' k = .84, F(1, 122) = 23.04, p < .001 although anxiety outcomes did not differ by treatment condition, Wilks' k = 1.00, F(1, 122) = 0.67, p > .05. Similarly, depression improved across treatment, Wilks' k = .76, F(1, 122) = 39.67, p < .001 although again, there was no effect for treatment condition, Wilks' k = 1.00, F(1, 122) = 0.25, p > .05.
A repeated-measures MANOVA demonstrated a significant multivariate effect on anxiety, Wilks' k = .80, F(1, 92) = 22.38, p < .001 and depression Wilks' k = .68, F(1, 92) = 44.32, p < .001 although there were differences in anxiety or depression reduction by treatment condition (p's > .05).
Treatment follow-up effects Amongst treatment completers, 75% of participants (ERP + CT: N = 39; ERP; N = 31) were retained for their 6-month follow-up assessment. A MANOVA with treatment modality as the between-group independent variable and Y-BOCS at baseline and 6-month follow-up as the within-group repeated measures demonstrated a main effect for Y-BOCS change, Wilks' k = .34, F(1, 68) = 134.77, p < .001 and a two-way Y-BOCS change by treatment condition interaction, Wilks' k = .94, F(1, 68) = 4.47, p < .05 with the ERP + CT group producing greater reduction in Y-BOCS scores from baseline to 6-month follow-up than the ERP group.
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Discussion
Main findings
While large gains have been made in recent decades towards improving treatment for OCD, a substantial proportion of clients fail to show clinically significant change (Fisher & Wells, 2005) , suggesting that further improvements can yet be made to existing treatments. Consistent with previous research, both ERP and ERP + CT were found to be highly efficacious treatments with significant and statistically large reductions in O-C symptoms at post-treatment. There were also significant differences between treatment conditions: Integrated ERP + CT led to comparatively greater reductions in O-C symptoms at post-treatment compared with ERP alone. This additive benefit was equivalent to a medium to large treatment effect. This pattern of treatment effects was observed regardless of whether the treatment groups were compared in the ITT or the treatment completer samples. Employing a rigorous 50% symptom reduction cut-off to determine treatment response status and achieve a 'mild illness' designation (Tolin et al., 2005) , a significant difference was observed with more participants deemed recovered in ERP + CT than ERP. The additive benefits that were found were shown to be efficacious across the main OCD dimensions addressed in the study: contamination/washing, doubting-harming/checking, order-symmetry/repeating and pure obsession (harming, sexual, somatic, and religious). Overall, these results suggest that the integration of cognitive therapy into the well-validated ERP approach to OCD may lead to clinically significant additive benefits beyond ERP alone.
In the ITT and treatment completer analyses, both ERP and ERP + CT produced medium-to-large and equivalent effects on general symptoms of anxiety and depression. However, ERP + CT was found to produce greater change on the underlying obsessive beliefs that are seen to constitute vulnerability to the development and persistence of the disorder within current cognitive frameworks (Clark, 2004; OCCWG, 1997 OCCWG, , 2001 OCCWG, , 2003 Rachman, 1997 Rachman, , 1998 Salkovskis, 1985 Salkovskis, , 1999 . These results suggest that the additive benefits of ERP + CT compared to ERP appear to be specific to the symptomatic and cognitive aspects of OCD and cannot be explained in terms of non-specific therapy factors. In further support of this interpretation, the differential treatment effects in favour of ERP + CT compared with ERP were not due to other therapeutic factors such as treatment expectations or differences in adherence to protocols. Moreover, differences in outcome were not due to medication use which was rigorously monitored and controlled.
The significantly larger effect of ERP + CT on obsessive beliefs is somewhat of a departure from previous research findings comparing CT to ERP, in which the treatments were found to have equivalent effects on obsessive beliefs at post-treatment (Whittal et al., 2005) . As this study differed from previous research in that CT and ERP were integrated and then compared to ERP, it is possible that the addition of the two interventions creates a stronger synergistic treatment for obsessive beliefs than either intervention alone. On the one hand, ERP may be enhanced through the direct treatment targeting of obsessive appraisals and beliefs during in-and between-session exposure tasks and as part of modular targeting of obsessive beliefs. On the other hand, CT may be enhanced through the greater experiential learning that follows from frequent anxietyinducing exposure tasks compared to the previous reliance of CT on behavioural experiments that focused on data collection pertaining to testing threat appraisals.
Strengths and limitations
The current study has several limitations. First, the study did not employ a waitlist condition to examine the differential effects of ERP or ERP + CT versus another form of psychotherapy. However, past research has demonstrated only modest treatment gains in non-CBT psychotherapy interventions for OCD (e.g., d < 0.20; Eddy et al., 2004) and this study did permit the direct examination of two active psychological treatments while controlling for the influence of medication use. Second, because the examination of OCD subtype outcomes was exploratory, the subtype analysis was based on previously established categories using the Y-BOCS rather than on a validated dimensional measure. These results will require replication with more reliable and valid dimensional O-C measures and with more larger sample sizes for each symptom dimension (Abramowitz et al., 2010) . However, these preliminary subtyping results do suggest promise for the beneficial effects of integrated ERP + CT for the range of O-C symptom dimensions opposed to a single symptom dimension (i.e., 'bad thoughts'). Third, participants were permitted to have dimensionally elevated depressive symptoms, but the presence of a diagnosable mood disorder was the basis for exclusion which may limit the external validity of the study given the high rates of depression comorbidity in community and clinical samples (see Rector, Wilde, & Richter, 2017 for review of epidemiological, clinical, and treatment aspects of depression/OCD comorbidity). Past research with ERP Abramowitz, Franklin, Street, Kozak, & Foa, 2000) has demonstrated that depressive symptoms in the mild-tomoderate range do not adversely impact on the efficacy of ERP whereas the presence of severe depressive symptoms or diagnosable MDD does predict worse treatment outcomes at post-treatment and follow-up. Less is known about the impact of comorbid depression on response to CT although a study by McLean et al. (2001) found that 'treatment responders' to both ERP and CT for OCD were found to have lower depression scores than non-responders. The current study was unable to test the moderating influence of MDD on integrated ERP + CT treatment outcomes, and this will require future examination. Fourth, the pre-post treatment effect size for the ERP group (d = 1.27) was found to be somewhat smaller than observed in some other ERP treatment studies, though within the range of ERP treatment effects reported in metaanalytic reviews (e.g., d = 1.53; d = 1.13; Eddy et al., 2004; Rosa-Alc azar et al., 2008) . One possible explanation for the lower ERP effect size compared to previous findings is that the ERP treatment in this study consisted of once-weekly 60 min sessions, rather than more intensive ERP of two or more weekly sessions that have been frequently described in the literature (Foa et al., 2005) . More intensive ERP generally results in higher effect sizes at post-treatment compared to less intensive (J onsson, Kristensen, & Arendt, 2015) . Importantly, the once-weekly 60-min session in the current study may represent the more typical outpatient delivery of ERP in the community. Moreover, the pre-post treatment effect (d = 1.89) for the combined treatment in the current study exceeds the typically reported pre-post effects for ERP alone. Despite these limitations, the findings of the current study provide evidence supporting NICE (2005) treatment guidelines that recommend the integration of ERP and CT for optimal treatment outcome in OCD.
